Expert panelists Harry P. Erba, MD, PhD; Jamile M. Shammo, MD, FASCP, FACP; Srdan Verstovsek, MD, PhD; and Ruben A. Mesa, MD, FACP, elucidate the importance of developing novel therapies in the setting of myeloproliferative neoplasms and discuss the emerging novel JAK2 inhibitors.

свернуть